Madrigal Pharmaceuticals
MDGL
144 hedge funds and large institutions have $1.01B invested in Madrigal Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 44 increasing their positions, 41 reducing their positions, and 15 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
93% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 15
16% more capital invested
Capital invested by funds: $876M → $1.01B (+$136M)
14% more call options, than puts
Call options by funds: $9.96M | Put options by funds: $8.75M
8% more funds holding
Funds holding: 133 → 144 (+11)
3.78% more ownership
Funds ownership: 66.14% → 69.92% (+3.8%)
7% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 41
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.9M |
| 2 |
AC
Armistice Capital
New York
|
+$7.23M |
| 3 |
PA
Perceptive Advisors
New York
|
+$7.1M |
| 4 |
AAA
Affinity Asset Advisors
New York
|
+$5.34M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.1M |
| 2 |
Goldman Sachs
New York
|
-$4.08M |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$3.07M |
| 4 |
Two Sigma Advisers
New York
|
-$2.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.4M |
MDGL Hedge Fund Activity: Q4 2021 in Review
144 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2021, worth a combined $1.01B — up 16% from $876M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new MDGL positions and 15 closed out — a net gain of 14 holders — while 44 added to existing stakes and 41 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $24.9M. The largest seller was State Street, cutting an estimated $13.1M.
- 144 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2021, up from 133 in Q3 2021.
- Funds reported $1.01B of Madrigal Pharmaceuticals stock for Q4 2021, up 16% quarter-over-quarter.
- 29 funds opened new Madrigal Pharmaceuticals positions in Q4 2021 and 15 closed out, a net change of +14 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2021 was Wellington Management Group, an estimated $24.9M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2021 was State Street, an estimated $13.1M sold.
Based on aggregated 13F filings for Q4 2021.